Breast Cancer

A drug withdrawal in follicular lymphoma and epithelioid sarcoma, a CRL in lung cancer, and priority review in breast cancer highlight this week's top oncology news.

PMD-026 inhibits RSK to block tumor growth signals and ER activity, a potential strategy to overcome CDK4/6 inhibitor resistance in breast cancer.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Laura J. Esserman, MD, MBA, discusses the potential utility of risk-based screening for breast cancer.

Javid Moslehi, MD, discusses the role of the cardiologist in the setting of breast cancer management to facilitate optimal cancer management.

Javid Moslehi, MD, highlights current cardiac monitoring protocols associated with breast cancer drugs and ways to refine these protocols in the future.

Laura J. Esserman, MD, MBA, discusses key results from the WISDOM 1.0 breast cancer screening trial.

Javid Moslehi, MD, explains the intersection of cardiovascular health and oncology when optimizing breast cancer treatment decision-making.

Laura J. Esserman, MD, MBA, explains current gaps with breast cancer screening methods.

Giredestrant plus palbociclib did not yield a statistically significant PFS improvement in ER-positive/HER2-negative locally advanced or metastatic breast cancer.

Findings presented at the Miami Breast Cancer Conference support using T-DXd across a wide range of real-world patients in community cancer settings.

Drs McCann and Nunnery share their stories and perspectives as leading women in oncology in honor of International Women's Day.

Kevin Kalinsky, MD, MS, FASCO, notes insights from a molecular tumor board discussion about the optimal management of HR-positive metastatic breast cancer.

The top 5 OncLive TV videos of the week cover insights in mantle cell lymphoma, breast cancer, bladder cancer, head and neck cancer, and pancreatic cancer.

The FDA approved a teclistamab combination in relapsed/refractory myeloma, Pylarify TruVu for PSMA-PET imaging in prostate cancer, and more.

Meghan R. Flanagan, MD, MPH, noted the nuanced discussions that multidisciplinary tumor boards should have to optimize breast cancer management strategies.

Patricia Jakel, MSN, notes the factors that influence breast cancer care, as exemplified in a discussion at the 43rd Annual Miami Breast Cancer Conference.

Zovegalisib plus fulvestrant drove responses in HR-positive, HER2-negative, PIK3CA-mutant advanced breast cancer

Lillian Rodich, MSPAS, MPH, highlights ways that medical oncologists can counsel patients with breast cancer about integrative medicine modalities.

W. Fraser Symmans, MD, discusses data on the current state of AI-driven digital pathology in HR+ breast cancer.

Dato-DXd plus durvalumab showed promising efficacy in locally advanced or metastatic triple-negative breast cancer.

Heather A. Parsons, MD, MPH, shares growing evidence for the prognostic value of circulating tumor DNA in early-stage breast cancer.

Ultra-hypofractionted radiotherapy yielded responses in locally advanced breast cancer.

T-DXd was associated with low rates of real-world discontinuation in HER2-low metastatic breast cancer.

Ana C. Garrido-Castro, MD, discusses the implications of 3 of the biggest phase 3 TNBC trials from 2025 and how they may reshape frontline management.